Krishna Institute of Medical Sciences Limited (KIMS) Fair Value & Analysis
Healthcare · IN · Market cap ₹335B
Fair value as of: Jul 3, 2026
From 14 valuation models · updated yesterday
Share price +15.4% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹573.38 – ₹837.90 · fair‑value band ₹76.92 – ₹177.09 · the ₹837.90 price screens above the ₹116.53 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Krishna Institute of Medical Sciences Limited (KIMS) currently trades at ₹837.90, while our model-based Fair Value estimate is ₹116.53 — implying the stock looks roughly 86.1% overvalued today. We read business quality at 53/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Krishna Institute of Medical Sciences Limited generated revenue of ₹39.0B at a net margin of 6.2%. Revenue grew 34.8% year over year. It earns a return on equity of 9.7%. Net debt stands at ₹41.8B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Krishna Institute of Medical Sciences Limited provides medical and health care services under the KIMS Hospitals brand in India. The company offers arthroscopy and shoulder, cardiology, cardiothoracic and cardiovascular, organ transplant, medical and surgical gastroenterology, hepatology, orthopaedic, neurology, neurosurgery, nephrology, urology, oncology, pediatric, neonatology, obstetrics and gynaecology, fertility, dental science, emergency and critical care, vascular, rehabilitation and physiotherapy services. It also provides pulmonology, diagnostic and imaging, ophthalmology, ENT, rheumatology and clinical immunology, internal medicine, interventional radiology, diabetology, endocrinology, general surgery, infectious disease, dermatology, thoracic surgery, psychiatry, plastic and reconstructive surgery, transfusion medicine, clinical psychology, anesthesiology, and tele medicine services. In addition, the company operates clinical immunology allergy, bone marrow …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Krishna Institute of Medical Sciences Limited reported revenue of ₹39.0B in FY2026 versus ₹16.5B in FY2022, a compound +24.0%/yr. Reported net income was ₹2.4B in FY2026, compounding −7.7%/yr from FY2022.
Is KIMS fairly valued? → Check now
Similar stocks
6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$97.60 | R$115.75 | +19% |
| Fresenius SE FSNUY | $11.27 | $8.25 | -27% |
| Q0F Q0F | 2.76 SGD | 1.28 SGD | -54% |
| 5225 5225 | 8.70 MYR | 2.61 MYR | -70% |
| IHHHF IHHHF | $1.71 | $1.26 | -26% |
| Rede D'Or São Luiz S.A RDOR3 | R$33.83 | R$46.94 | +39% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Krishna Institute of Medical Sciences Limited (KIMS) undervalued?
What is the fair value of KIMS?
What is the quality score of KIMS?
What is the revenue of Krishna Institute of Medical Sciences Limited (KIMS)?
What is the net profit margin of KIMS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.